[Difficulties of selecting patients to receive treatment against hepatitis C virus in patients with HIV coinfection].
Marcos Sánchez
F
F
Albo Castaño
M I
MI
Martín Barranco
M J
MJ
Casallo Blanco
S
S
Joya Seijo
D
D
Del Valle Loarte
P
P
D015526:AIDS Dementia Complex / Q000150:complications; D000140:Acidosis, Lactic / Q000139:chemically induced; D000437:Alcoholism / Q000150:complications; D000740:Anemia / Q000139:chemically induced; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015331:Cohort Studies; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007970:Leukopenia / Q000209:etiology; D008111:Liver Function Tests; D010195:Pancreatitis / Q000139:chemically induced; D018579:Patient Selection; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a